Cargando…

Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes

PURPOSE: Perfusion-weighted MRI (PWI) and O-(2-[(18)F]fluoroethyl-)-l-tyrosine ([(18)F]FET) PET are both applied to discriminate tumor progression (TP) from treatment-related changes (TRC) in patients with suspected recurrent glioma. While the combination of both methods has been reported to improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Steidl, Eike, Langen, Karl-Josef, Hmeidan, Sarah Abu, Polomac, Nenad, Filss, Christian P., Galldiks, Norbert, Lohmann, Philipp, Keil, Fee, Filipski, Katharina, Mottaghy, Felix M., Shah, Nadim Jon, Steinbach, Joachim P., Hattingen, Elke, Maurer, Gabriele D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113145/
https://www.ncbi.nlm.nih.gov/pubmed/33241456
http://dx.doi.org/10.1007/s00259-020-05114-0
_version_ 1783690799479783424
author Steidl, Eike
Langen, Karl-Josef
Hmeidan, Sarah Abu
Polomac, Nenad
Filss, Christian P.
Galldiks, Norbert
Lohmann, Philipp
Keil, Fee
Filipski, Katharina
Mottaghy, Felix M.
Shah, Nadim Jon
Steinbach, Joachim P.
Hattingen, Elke
Maurer, Gabriele D.
author_facet Steidl, Eike
Langen, Karl-Josef
Hmeidan, Sarah Abu
Polomac, Nenad
Filss, Christian P.
Galldiks, Norbert
Lohmann, Philipp
Keil, Fee
Filipski, Katharina
Mottaghy, Felix M.
Shah, Nadim Jon
Steinbach, Joachim P.
Hattingen, Elke
Maurer, Gabriele D.
author_sort Steidl, Eike
collection PubMed
description PURPOSE: Perfusion-weighted MRI (PWI) and O-(2-[(18)F]fluoroethyl-)-l-tyrosine ([(18)F]FET) PET are both applied to discriminate tumor progression (TP) from treatment-related changes (TRC) in patients with suspected recurrent glioma. While the combination of both methods has been reported to improve the diagnostic accuracy, the performance of a sequential implementation has not been further investigated. Therefore, we retrospectively analyzed the diagnostic value of consecutive PWI and [(18)F]FET PET. METHODS: We evaluated 104 patients with WHO grade II–IV glioma and suspected TP on conventional MRI using PWI and dynamic [(18)F]FET PET. Leakage corrected maximum relative cerebral blood volumes (rCBV(max)) were obtained from dynamic susceptibility contrast PWI. Furthermore, we calculated static (i.e., maximum tumor to brain ratios; TBR(max)) and dynamic [(18)F]FET PET parameters (i.e., Slope). Definitive diagnoses were based on histopathology (n = 42) or clinico-radiological follow-up (n = 62). The diagnostic performance of PWI and [(18)F]FET PET parameters to differentiate TP from TRC was evaluated by analyzing receiver operating characteristic and area under the curve (AUC). RESULTS: Across all patients, the differentiation of TP from TRC using rCBV(max) or [(18)F]FET PET parameters was moderate (AUC = 0.69–0.75; p < 0.01). A rCBV(max) cutoff > 2.85 had a positive predictive value for TP of 100%, enabling a correct TP diagnosis in 44 patients. In the remaining 60 patients, combined static and dynamic [(18)F]FET PET parameters (TBR(max), Slope) correctly discriminated TP and TRC in a significant 78% of patients, increasing the overall accuracy to 87%. A subgroup analysis of isocitrate dehydrogenase (IDH) mutant tumors indicated a superior performance of PWI to [(18)F]FET PET (AUC = 0.8/< 0.62, p < 0.01/≥ 0.3). CONCLUSION: While marked hyperperfusion on PWI indicated TP, [(18)F]FET PET proved beneficial to discriminate TP from TRC when PWI remained inconclusive. Thus, our results highlight the clinical value of sequential use of PWI and [(18)F]FET PET, allowing an economical use of diagnostic methods. The impact of an IDH mutation needs further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-020-05114-0.
format Online
Article
Text
id pubmed-8113145
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-81131452021-05-12 Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes Steidl, Eike Langen, Karl-Josef Hmeidan, Sarah Abu Polomac, Nenad Filss, Christian P. Galldiks, Norbert Lohmann, Philipp Keil, Fee Filipski, Katharina Mottaghy, Felix M. Shah, Nadim Jon Steinbach, Joachim P. Hattingen, Elke Maurer, Gabriele D. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Perfusion-weighted MRI (PWI) and O-(2-[(18)F]fluoroethyl-)-l-tyrosine ([(18)F]FET) PET are both applied to discriminate tumor progression (TP) from treatment-related changes (TRC) in patients with suspected recurrent glioma. While the combination of both methods has been reported to improve the diagnostic accuracy, the performance of a sequential implementation has not been further investigated. Therefore, we retrospectively analyzed the diagnostic value of consecutive PWI and [(18)F]FET PET. METHODS: We evaluated 104 patients with WHO grade II–IV glioma and suspected TP on conventional MRI using PWI and dynamic [(18)F]FET PET. Leakage corrected maximum relative cerebral blood volumes (rCBV(max)) were obtained from dynamic susceptibility contrast PWI. Furthermore, we calculated static (i.e., maximum tumor to brain ratios; TBR(max)) and dynamic [(18)F]FET PET parameters (i.e., Slope). Definitive diagnoses were based on histopathology (n = 42) or clinico-radiological follow-up (n = 62). The diagnostic performance of PWI and [(18)F]FET PET parameters to differentiate TP from TRC was evaluated by analyzing receiver operating characteristic and area under the curve (AUC). RESULTS: Across all patients, the differentiation of TP from TRC using rCBV(max) or [(18)F]FET PET parameters was moderate (AUC = 0.69–0.75; p < 0.01). A rCBV(max) cutoff > 2.85 had a positive predictive value for TP of 100%, enabling a correct TP diagnosis in 44 patients. In the remaining 60 patients, combined static and dynamic [(18)F]FET PET parameters (TBR(max), Slope) correctly discriminated TP and TRC in a significant 78% of patients, increasing the overall accuracy to 87%. A subgroup analysis of isocitrate dehydrogenase (IDH) mutant tumors indicated a superior performance of PWI to [(18)F]FET PET (AUC = 0.8/< 0.62, p < 0.01/≥ 0.3). CONCLUSION: While marked hyperperfusion on PWI indicated TP, [(18)F]FET PET proved beneficial to discriminate TP from TRC when PWI remained inconclusive. Thus, our results highlight the clinical value of sequential use of PWI and [(18)F]FET PET, allowing an economical use of diagnostic methods. The impact of an IDH mutation needs further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-020-05114-0. Springer Berlin Heidelberg 2020-11-26 2021 /pmc/articles/PMC8113145/ /pubmed/33241456 http://dx.doi.org/10.1007/s00259-020-05114-0 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Steidl, Eike
Langen, Karl-Josef
Hmeidan, Sarah Abu
Polomac, Nenad
Filss, Christian P.
Galldiks, Norbert
Lohmann, Philipp
Keil, Fee
Filipski, Katharina
Mottaghy, Felix M.
Shah, Nadim Jon
Steinbach, Joachim P.
Hattingen, Elke
Maurer, Gabriele D.
Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes
title Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes
title_full Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes
title_fullStr Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes
title_full_unstemmed Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes
title_short Sequential implementation of DSC-MR perfusion and dynamic [(18)F]FET PET allows efficient differentiation of glioma progression from treatment-related changes
title_sort sequential implementation of dsc-mr perfusion and dynamic [(18)f]fet pet allows efficient differentiation of glioma progression from treatment-related changes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113145/
https://www.ncbi.nlm.nih.gov/pubmed/33241456
http://dx.doi.org/10.1007/s00259-020-05114-0
work_keys_str_mv AT steidleike sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT langenkarljosef sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT hmeidansarahabu sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT polomacnenad sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT filsschristianp sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT galldiksnorbert sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT lohmannphilipp sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT keilfee sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT filipskikatharina sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT mottaghyfelixm sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT shahnadimjon sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT steinbachjoachimp sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT hattingenelke sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges
AT maurergabrieled sequentialimplementationofdscmrperfusionanddynamic18ffetpetallowsefficientdifferentiationofgliomaprogressionfromtreatmentrelatedchanges